InvestorsHub Logo
Followers 43
Posts 837
Boards Moderated 0
Alias Born 08/25/2020

Re: None

Sunday, 02/07/2021 10:03:17 AM

Sunday, February 07, 2021 10:03:17 AM

Post# of 199990
I wanted to reflect on the statement from the FDA as far as their focus on monoclonal antibodies. They stated that they’re aware that some of the monoclonal antibodies that are already in production may have limited or no effectiveness against new varietents of covid. They’re now looking at working with bio companies that can prevent the mutation of the virus using monoclonal antibodies. They also stated that they’re exploring relaxing the regulatory process to help expedite this process. I have a few simple qualifying questions to help make an educated guess as to who they may be referring to. 1) What is the claim of ENZC about their clone 3 monoclonal antibody? It targets areas of the virus that makes mutation a non issue. Does anyone know of another company making this claim? 2) Does anyone know of a company making this claim that is infront of the big pharma companies participating in operation warp speed as well as the FDA at Texas A&M? This may be jumping the gun but logical reasoning leads a well intentioned common sense person to guess that they just said that they’re putting their chips into ENZC as the light at the end of the tunnel and they’re looking at changing the rules slightly to make it happen faster. I’m very optimistic that the end of the pandemic could be near and ENZC is the holder of the answer.